Skip to main content

A new era for the Innovative Licensing and Access Pathway (ILAP)

6 November 2024

The Innovative Licensing and Access Pathway (ILAP) is entering a new era that is focussed on getting the most transformative new medicines to patients in the National Health Service (NHS) more quickly.  

The ILAP aims to accelerate the time to patient access for transformative new medicines, by providing a single integrated platform for sustained collaborative working between the developer, the regulator (MHRA), the National Health Service (NHS) and the UK Health Technology Assessment (HTA) bodies who are; the All Wales Therapeutics and Toxicology Centre (AWTTC), the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC).  

The key enhancements to the pathway are:  

  • Better quality bespoke service through more selective entry and more frequent dialogue between the ILAP partners and the developer.   
  • Simpler roadmap and more predictable timelines, enabling developers to plan more effectively.  
  • The NHS will be involved as a core partner and will bring a focus on operational planning and system preparedness for the introduction of innovative new medicines into the NHS for the benefit of patients. Exclusive access to ILAP Joint Scientific Advice and the Access Forums which uniquely span regulatory, HTA and healthcare system expertise across England, Scotland and Wales.  
  • Prioritised scheduling of the ILAP Joint Scientific Advice (JSA), the ILAP Access Forums, the MHRA scientific advice and pre-submission meetings and access to Clinical Practice Research Datalink (CPRD).   
  • Broadening the ILAP to include medicine-device combinations.

 

Patient and public involvement are integral to the ILAP, and plans are underway to embed the patient voice in a meaningful way in the pathway.  In addition, the ILAP partners will continue to engage with the life sciences sector to ensure the new ILAP delivers for developers, the NHS and patients and the public.  

For more information visit Innovative Licensing and Access Pathway - GOV.UK 

Follow AWTTC: